stockrow
Friday 6 November 2026
Export VKTX’s income statement to Excel — free account
Viking Therapeutics, Inc.
VKTX Healthcare Biotechnology
- EPS
- −91.6%
- Free cash flow
- −47.0%
Quarter to September 2026, against a year earlier
26.79
1.00
+3.88%
Follow VKTX
Alert me
Viking Therapeutics, Inc. (VKTX) Shares outstanding
Viking Therapeutics, Inc.'s shares outstanding at the end of fiscal 2025 was $112.7M, unchanged from fiscal 2024. At the end of the quarter to 30 September 2026 it was $118.1M. Over the past ten years it has ranged from $6.4M (fiscal 2015) to $112.7M (fiscal 2025) — the current reading is the highest in ten years. Viking Therapeutics, Inc. ranks 113th of 600 Biotechnology companies by shares outstanding.
Shares outstanding, annual
Embed this chart
Annual newest first
| Period | Shares outstanding | Change |
|---|---|---|
| FY2025 | $112.7M | 3.33% |
| FY2024 | $109.0M | 15.57% |
| FY2023 | $94.3M | 22.79% |
| FY2022 | $76.8M | (0.47%) |
| FY2021 | $77.2M | 6.34% |
| FY2020 | $72.6M | 0.89% |
| FY2019 | $72.0M | 24.97% |
| FY2018 | $57.6M | 121.65% |
| FY2017 | $26.0M | 59.59% |
| FY2016 | $16.3M | 156.10% |
Quarterly newest first
| Period | Shares outstanding | Change |
|---|---|---|
| Sep 2026 | $118.1M | 1.54% |
| Jun 2026 | $116.3M | 0.60% |
| Mar 2026 | $115.6M | 2.57% |
| Dec 2025 | $112.7M | 0.31% |
| 43 more quarters | Free account |
Against its own ten years
Low $6.4M
High $112.7M
Ten-year median
$72.6M
Current reading's percentile
100
Shares outstanding against peers
| Company | Shares outstanding |
|---|---|
| ACAD ACADIA Pharmaceuticals Inc. compare | $175.5M |
| DYN Dyne Therapeutics, Inc. compare | $165.5M |
| VKTX Viking Therapeutics, Inc. | $118.1M |
| XENE Xenon Pharmaceuticals Inc. compare | $99.6M |
| ELVN Enliven Therapeutics, Inc. compare | $66.2M |
| CELC Celcuity, Inc. compare | $54.8M |
| TARS Tarsus Pharmaceuticals, Inc. compare | $46.4M |
| IRON Disc Medicine, Inc. compare | $38.7M |
| PBLS Parabilis Medicines, Inc. compare | $28.9M |
What Shares outstanding is
Shares (Diluted, Weighted) tells an investor how many shares a company’s earnings are spread across once potential new shares are counted.
Reported line item